Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
JERSEY, Channel Islands, Feb. 22, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA. Also participating in the conference will be the Company’s Chief Financial Officer, Chris Lindop.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
